Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday

Vera Therapeutics (NASDAQ:VERA) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Trading Up 1.2 %

Shares of VERA opened at $27.99 on Monday. The firm’s 50-day moving average price is $33.01 and its 200-day moving average price is $39.64. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -10.72 and a beta of 1.17. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a 1-year low of $25.99 and a 1-year high of $51.61.

Insiders Place Their Bets

In other news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the transaction, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at $5,993,989.22. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 21.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on VERA shares. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective on the stock. Wells Fargo & Company started coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective on the stock. Guggenheim boosted their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Wolfe Research started coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.